Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.
The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis. A second clinical-stage program, CBP-701, selectively inhibits signaling through tumor necrosis factor receptor 1 (TNFR1), a strategy designed to preserve beneficial TNFR2 activity while reducing the risk of systemic immunosuppression. Together, these candidates reflect Connect Biopharma’s commitment to developing differentiated therapies with potentially improved safety and efficacy profiles.
Since its founding in 2015, Connect Biopharma has advanced its pipeline through early-phase clinical trials and established strategic partnerships to support long-term development goals. The company completed its initial public offering on the Nasdaq Global Market under the ticker CNTB in 2021, raising capital to fund ongoing studies and expand its research capabilities. Its clinical programs are being evaluated across multiple geographies, including North America and the Asia-Pacific region.
Connect Biopharma is led by an executive team and board of directors with extensive experience in biotechnology, pharmaceutical development and commercialization. Leveraging a blend of scientific rigor and clinical expertise, the management group aims to bring novel immunology treatments to patients with high unmet medical need.
AI Generated. May Contain Errors.
Free CNTB Stock Alerts